Andrew Meads

Andrew Meads has a strong background in medical writing and clinical development. Andrew is currently the Senior Director of Medical Writing at UroGen Pharma, a position they have held since January 2023. Prior to this, they served as the Director of Medical Writing at the same company from August 2020 to January 2023.

Before joining UroGen Pharma, Andrew worked at Nabriva Therapeutics plc from October 2016 to July 2020. Here, they held the role of Director of Clinical Development and Medical Writing from January 2019 to July 2020 and Associate Director of Clinical Development and Medical Writing from October 2016 to December 2018.

Andrew's previous experience includes working as the Principal Medical Writer at CSL Behring from July 2015 to September 2016, and as the Manager of Medical Writing at ViroPharma Incorporated/Shire plc from January 2012 to June 2015. Andrew also held the position of Senior Technical Editor of Medical Writing at ViroPharma Incorporated from January 2009 to December 2011.

Before transitioning into medical writing, Andrew gained experience as a Clinical Quality Control Associate at Centocor from May 2005 to December 2008.

Overall, Andrew Meads has a diverse and extensive career in medical writing and clinical development, demonstrating their expertise in the field.

Andrew Meads attended The University of Scranton from 2001 to 2005, where they pursued a BS/BA degree. Andrew then went on to The University of Pennsylvania from 2013 to 2014, where they undertook graduate coursework in the Department of Medical Ethics & Health Policy.